Sera Labs offers 1,500 recombinant proteins

Published: 1-Jun-2010
Research & Development

Including cytokines, growth factors, chemokines, hormones, enzymes and viral antigens

Sera Labs offers 1,500 recombinant proteins
Sera Laboratories International, a UK-based serum specialist, has developed more than 1,500 recombinant proteins for a variety of species including human, mouse, rat, porcine, bovine and chicken. The collection includes cytokines, growth factors, chemokines, hormones, enzymes and viral antigens.

Sera Lab’s recombinant proteins are mainly derived from bacterial systems and also include mammalian, yeast, insect and plant sources. All are rigorously tested to ensure excellent quality and biological activity.

With headquarters and storage in Haywards Heath, West Sussex and a cell culture research facility in France, Sera Lab offers a complete range of animal-based research products from a variety of origins. The company supplies laboratories in more than 30 countries worldwide, either directly or through distributors.

See more

You may also like

Research & Development
Adragos signs agreement with Towa Pharmaceutical to supply off-patent medicines

Adragos signs agreement with Towa Pharmaceutical to supply off-patent medicines

Read more
Adragos Pharma Kawagoe KK has announced the signing of an agreement with Towa Pharmaceutical Co., Ltd, to establish a strategic collaboration aimed at ensuring the stable supply of off-patent pharmaceuticals

Trending Articles

  1. World-first gene therapy to target devastating rare immune disorder Early preclinical studies have shown encouraging results, with corrected cells demonstrating improved control of immune activity
  2. SIRO Clinpharm expands its presence in Asia Launches operations in Malaysia
  3. BioDuro and CTI Technology partner to push forward preclinical drug development The duo will combine their manufacturing experience and analytical capabilities to build an integrated platform spanning all the way from drug discovery to IND submission to accelerate the drug development path for clients
  4. SCIEX supports cancer survival research through donation to World Cancer Research Fund The $17,500 donation will fund research investigating the correlations between food, nutrition and exercise with cancer prognosis and outcomes in cancer survivors
  5. Shift Bioscience establishes North American presence to advance rejuvenation gene target discovery The biotech has expanded into North America with its new facility in Toronto, Canada — which will aid in the advancement of rejuvenation gene target discovery

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Research & Development
Adragos signs agreement with Towa Pharmaceutical to supply off-patent medicines

Adragos signs agreement with Towa Pharmaceutical to supply off-patent medicines

Adragos Pharma Kawagoe KK has announced the signing of an agreement with Towa Pharmaceutical Co., Ltd, to establish a strategic collaboration aimed at ensuring the stable supply of off-patent pharmaceuticals
Manufacturing
SCHOTT Pharma and SHL Medical enhance home-based large-volume injections for patients

SCHOTT Pharma and SHL Medical enhance home-based large-volume injections for patients

SCHOTT Pharma and SHL Medical have joined forces to introduce the first large-volume cartridge in an autoinjector
Regulatory
Sanofi expands vaccine manufacturing in Abu Dhabi as NICE backs its diabetes therapy

Sanofi expands vaccine manufacturing in Abu Dhabi as NICE backs its diabetes therapy

Sanofi advances on two fronts: a new Abu Dhabi vaccine innovation centre with AI and mRNA capabilities and UK NICE backing for teplizumab, the first disease-modifying treatment for type 1 diabetes
Research & Development
PharmNovo reports broader therapeutic potential for PN6047

PharmNovo reports broader therapeutic potential for PN6047

PharmNovo AB has announced new preclinical findings supporting the potential of PN6047 in migraine and opioid withdrawal syndrome. The findings were generated through the company's NIDA-funded collaboration with researchers at Washington University School of Medicine
Sustainability
Haier Biomedical introduces higher capacity benchtop centrifuge with rapid pre-cooling

Haier Biomedical introduces higher capacity benchtop centrifuge with rapid pre-cooling

Haier Biomedical – a trusted partner in reliable laboratory equipment – has introduced the LX-155T750R, its latest high-speed, benchtop centrifuge featuring ECO fastBlast pre-cooling technology
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development
Neuropsychiatric medicine reaches an inflexion point: regulation, science and the road to commercial reality

Neuropsychiatric medicine reaches an inflexion point: regulation, science and the road to commercial reality

Shaped by accelerating regulatory support, expanding clinical evidence and growing institutional acceptance, psychedelic medicine is entering a pivotal phase, reports Joel Latham, Chief Executive Officer, President and Director at Incannex Healthcare Inc.
Research & Development
World-first gene therapy to target devastating rare immune disorder

World-first gene therapy to target devastating rare immune disorder

Early preclinical studies have shown encouraging results, with corrected cells demonstrating improved control of immune activity
Subscribe now